Tuesday, January 31, 2017 10:46:23 AM
A major patent settlement between Merck & Co. and Bristol-Myers Squibb was one of last week's biggest healthcare stories.
Motley Fool Staff (the_motley_fool) Jan 31, 2017 at 9:08AM
After Bristol-Myers Squibb (NYSE:BMY) claimed Merck & Co.'s (NYSE:MRK) cancer-fighting Keytruda infringed upon patents protecting Opdivo, Merck & Co. has agreed to pay Bristol-Myers Squibb $625 million up-front, plus future royalties, in exchange for a non-exclusive license to Opdivo's intellectual property. Does this deal make Bristol-Myers Squibb shares a buy?
In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes sits down with Todd Campbell to discuss what was behind the deal, and how big the royalty payments may be.
A full transcript follows the video.
(VIDEO OMITTED)
This podcast was recorded on Jan. 25, 2017.
Kristine Harjes: Let's kick it off with Merck, and also Bristol-Myers.
Todd Campbell: Some very interesting news here this week, Kristine. Wouldn't you like to be able to add nine figures in revenue with just the stroke of a pen?
Harjes: Yeah, that would be nice. My bank account would love it.
Campbell: That's essentially what's happened here with Bristol-Myers and Merck. Essentially, these two companies have settled a patent dispute, Bristol-Myers coming out on top. Merck has now agreed to give them a pile of money up front to make up for royalties that they hadn't been paying for infringing on the patent. And, according to the settlement, Merck is going to give Bristol-Myers a healthy 6.5% dividend from here until 2023, and then another 2.5% from 2024 to 2026.
Harjes: And that's specifically on one drug named Opdivo and Keytruda.
Campbell: Yes. Both these drugs work in the same way, they target a protein called the PD-1, which is expressed on T-cells, in which cancer cells sneakily use to evade the immune system's detection.
Harjes: Right. This is a completely novel way of treating cancer, which is why you have Bristol-Myers saying here, "Hey, wait, you have infringed upon the patent that we have." So this will effectually end all of the patent infringement litigation against Merck's Keytruda, and as you mentioned, Bristol will get a whole pile of money to make up for the past, and then they'll get royalties going forwards. The payments will actually be split 75% to Bristol-Myers and 25% to a company called Ono Pharmaceutical, it's a Japanese partner on the drug. This is still a very hefty sum for Bristol-Myers.
Campbell: Right. They're getting $625 million right up front. Merry Christmas; here's $625 million! Then, if you look at the potential market opportunity for these checkpoint inhibitors, these PD-1 drugs, it's tremendous, it's huge. These are billions and billions dollar drugs. Just out of the gate, assuming no additional growth on Keytruda, you'd be looking at right around $100 million in royalties stream heading toward Bristol.
Harjes: Right, so this is huge news. Most likely, the drug will continue to expand, making it even bigger and bigger news going forward. And that 6.5% royalty will last all the way through the end of 2023.
Campbell: Right. You just mentioned to the ability to expand. A lot of cancers use this PD-1 to escape detection. What they're finding is, as they do more and more trials in different types of cancer, that these drugs are very effective, very high response rates in patients. This was especially interesting, to see them come to this agreement, because in the last year or so, both drugs, Opdivo and Keytruda, they've diverged in what's happened in their clinical trials, with Merck having a lot of success and Bristol-Myers mostly, in my view, because of the way they designed their trials, having less success, especially in lung cancer.
Harjes: Right. This is something we have talked about on a previous episode of Industry Focus, so our long-time listeners will hopefully remember. It basically had to do, as you mentioned, with the trial design, where Opdivo failed its trail in which it was looking at pretty much all levels of PD-1 expression 5% or above as opposed to, when they did the Keytruda study, it was 50% PD-1 expression and above. Of course, it's a drug that works on PD-1, so if you're targeting patients that have a higher expression of it, you're tilting the odds in your favor.
Campbell: Yeah, it's almost like Merck went the safe route, and Bristol-Myers tried to jump the shark.
Harjes: Right, and it backfired.
Campbell: By going the safe route, Merck was able to nab an FDA approval for the use of Keytruda in the first line setting for high-expressing PDL patients. What's really interesting is that they also have recently filed for first line use of Keytruda plus chemotherapy in patients who don't express PD-1, after seeing some pretty solid trials. So, if Bristol-Myers had either designed the trials so that was only high-expressing patients initially, or had combined it with chemotherapy, who knows if Keytruda would have the advantage in lung cancer heading into 2017 versus Opdivo. Obviously, I think that probably made Bristol-Myers a bit more willing to agree to that royalty stream, because they looked at it and said, "Well, if we can't get the first line, and the first line could be worth up to $1 billion, at least maybe we can share in some of Keytruda's success."
Harjes: Absolutely. It is not a bad consolation prize.
Campbell: No, and it's all high-margin money. They're not actually producing anything, they already produced the IP for it.
Kristine Harjes has no position in any stocks mentioned. Todd Campbell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
_______________________________________________
http://www.fool.com/investing/2017/01/31/merck-makes-nice-with-bristol-myers-squibb.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2
BMY
Recent BMY News
- Arm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and More • IH Market News • 05/13/2024 11:16:03 AM
- Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial • Business Wire • 05/10/2024 08:30:00 PM
- Bristol Myers Squibb to Participate in Upcoming Investor Conferences • Business Wire • 05/07/2024 10:59:00 AM
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite... • Business Wire • 05/06/2024 10:59:00 AM
- U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase) • Business Wire • 05/06/2024 10:59:00 AM
- Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases • PR Newswire (US) • 04/29/2024 10:00:00 AM
- CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma • Business Wire • 04/26/2024 10:59:00 AM
- U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast • IH Market News • 04/25/2024 11:53:54 AM
- Bristol Myers Squibb Reports First Quarter Financial Results for 2024 • Business Wire • 04/25/2024 10:59:00 AM
- Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News • IH Market News • 04/23/2024 11:25:34 AM
- Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster • Business Wire • 04/22/2024 10:59:00 AM
- Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster • Business Wire • 04/22/2024 10:59:00 AM
- KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) • Business Wire • 04/08/2024 03:30:00 PM
- Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society • Business Wire • 04/06/2024 05:15:00 PM
- Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society • Business Wire • 04/06/2024 05:15:00 PM
- U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy • Business Wire • 04/05/2024 01:05:00 PM
- European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) • Business Wire • 04/03/2024 12:08:00 AM
- Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals • Business Wire • 04/02/2024 10:59:00 AM
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung… • Business Wire • 03/28/2024 08:05:00 PM
- Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease • Business Wire • 03/28/2024 08:01:00 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:08 AM
- A Bristol Myers Squibb Expande as Iniciativas de Doações para a Equidade em Saúde a fim de Melhorar os Resultados de Saúde • Business Wire • 03/26/2024 06:25:00 PM
- Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes • Business Wire • 03/26/2024 10:59:00 AM
- Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio • Business Wire • 03/25/2024 12:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM